Molecular Partners Ag (MOLN) Other Working Capital Changes (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Other Working Capital Changes of $286.05 for Q1 2026, down 52.9% year-on-year from $607.29 in Q1 2025, and down 99.93% on a QoQ basis from $418978.0 in Q4 2025.
Molecular Partners Ag (MOLN) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other Working Capital Changes for 6 consecutive years, with $286.05 the latest figure, recorded in Q1 2026.
- Quarterly Other Working Capital Changes fell 52.9% year-over-year to $286.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $416066.2 (up 55.53% YoY) and the FY2025 annual result came in at $419141.9, up 54.93% from the prior year.
- Other Working Capital Changes slipped to -$383.1 in Q1 2026 per MOLN's latest filing, from $757676.4 in the prior quarter.
- Over the last five years, Other Working Capital Changes for MOLN reached as high as $757676.4 in Q3 2025 and fell as low as -$732823.4 in Q2 2025.
- A 5-year average of $4662.9 and a median of -$337.01 in 2025 frame the typical range for Other Working Capital Changes.
- The largest YoY upside for Other Working Capital Changes was 138.51% in 2022 against a maximum downside of 113.48% in 2022.
- Year by year, Other Working Capital Changes stood at $613103.2 in 2022, then increased by 10.26% to $676010.6 in 2023, then climbed by 2.8% to $694942.4 in 2024, then gained by 9.03% to $757676.4 in 2025, then slumped by 100.05% to -$383.1 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$383.1, $757676.4, and -$732823.4 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Molecular Partners Ag | 149.27 Mn | 149.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -383.10 |
| Mar 31, 2026 | -383.10 |
| Mar 31, 2026 | -383.10 |
| Sep 30, 2025 | 757,676.38 |
| Sep 30, 2025 | 757,676.38 |
| Sep 30, 2025 | 757,676.38 |
| Jun 30, 2025 | -732,823.38 |
| Jun 30, 2025 | -732,823.38 |
| Jun 30, 2025 | -732,823.38 |
| Mar 31, 2025 | -337.01 |
| Mar 31, 2025 | -337.01 |
| Mar 31, 2025 | -337.01 |
| Sep 30, 2024 | 694,942.41 |
| Sep 30, 2024 | 694,942.41 |
| Sep 30, 2024 | 694,942.41 |
| Jun 30, 2024 | -666,460.63 |
| Jun 30, 2024 | -666,460.63 |
| Jun 30, 2024 | -666,460.63 |
| Mar 31, 2024 | -344.85 |
| Mar 31, 2024 | -344.85 |